Malcolm Skolnick, CytoGenix Chief Executive Officer states, "As Controller, Ms. Schertz has done an outstanding job in managing the Company's financial records, preparing the Company's quarterly reports, and facilitating compliance with the Sarbanes-Oxley regulations. We are fortunate to have someone with her experience and ability to maintain continuity in this critical area of the Company's operations."
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com.
Contact: CytoGenix, Inc., Houston Malcolm Skolnick, 713-789-0070
Source: CytoGenix, Inc.
